ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1513

Clinical Characteristics and Peripheral Joint Involvement at the Time of Diagnosis of Non-Radiographic Axial Spondyloarthritis Patients in the United States and Europe

Atul A. Deodhar1, Theresa Hunter2, David Sandoval Calderon3, Steve Lobosco4, Rachel Moon4 and Gary Milligan5, 1Oregon Health & Science University, Portland, OR, 2Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN, 3Eli Lilly and Company, Indianapolis, IN, 4Adelphi Real World, Macclesfield, United Kingdom, 5Adelphi Real World, Macclesfield,, United Kingdom

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: axial spondyloarthritis, diagnosis, inflammatory back pain, non-radiographic and spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Timely identification of nr-axSpA may lead to earlier intervention to reduce symptoms, improve function, and reduce disease burden. The purpose of this study was to compare the clinical characteristics that are present at the time of diagnosis of nr-axSpA patients in the US and EU.

Methods: Nr-axSpA patients from the 2015 SpA Disease Specific Programme, a cross-sectional, multi-national survey of patients and rheumatologists conducted in France, Germany, Italy, Spain, United Kingdom, and the United States were analyzed. Rheumatologists completed patient record forms containing patient demographics, clinical measurements and symptomology at diagnosis.

Results: Data from 391 rheumatologists (299 EU/92 US) and 1,995 patients with nr-axSpA (1513 EU/482 US) were included in this analysis. In the US and EU, at the time of diagnosis patients had similar rates of IBP, back pain for more than 3 months, and a family history of SpA (Table 1). Patients in the US were significantly more likely to have peripheral joint involvement at diagnosis than patients in the EU. In the US, patients that had peripheral joint involvement at diagnosis were significantly more likely to have had IBP that was previously diagnosed as mechanical back pain (p=0.002) and have back pain for greater than 3 months (p=0.035) at diagnosis when compared to patients that did not have peripheral joint involvement at diagnosis. In the EU, patients that had peripheral joint involvement at diagnosis were significantly more likely to have elevated ESR (p<0.001) and alternating buttock pain (p=0.002) when compared to patients that did not have peripheral joint involvement at diagnosis. In the US and EU, patients that had peripheral joint involvement at diagnosis were significantly more likely to have elevated CRP, morning stiffness for more than 30 minutes, dactylitis, enthesitis, tendonitis, synovitis, and arthritis at diagnosis when compared patients that did not have peripheral joint involvement at diagnosis (Table 2).

Conclusion: Nr-axSpA patients in the US and EU share a range of clinical features at diagnosis. However, patients in the US were more likely to have peripheral joint involvement at diagnosis than patients in the EU. Furthermore, nr-axSpA patients in the US and EU with peripheral joint involvement at diagnosis were associated with a worse symptom profile versus patients without peripheral joint involvement.

Table 1. Comparison of symptoms of nr-axSpA patients at diagnosis in the US vs. EU

Symptoms at Diagnosis

USA

EU

p-value

% with symptom

% with symptom

Peripheral joint involvement

50.8

23.3

<0.0001

IBP or spinal pain

69.3

67.6

0.5016

Age of onset of IBP less than 45 years

48.5

48.2

0.9167

Back pain for more than 3 months

56.0

54.9

0.7128

IBP that was previously diagnosed as mechanical back pain

27.4

27.3

1.0000

Family history of spondyloarthritis

20.7

20.9

1.0000

Morning stiffness for more than 30 minutes

57.9

51.8

0.0210

Elevated CRP

37.1

37.1

1.0000

Elevated ESR

37.3

25.4

<0.0001

HLA-B27 positive

46.5

49.5

0.2293

Table 2. Comparison of symptoms of nr-axSpA patients with peripheral joint involvement at diagnosis vs. nr-axSpA patients without peripheral joint involvement at diagnosis

Symptoms at Diagnosis

USA

EU

% With Symptoms

p-value

% With symptoms

p-value

Back pain for < 3 months

60.8

0.0348

59.1

0.0764

IBP previously diagnosed as mechanical back pain

33.9

0.0015

30.1

0.1943

Morning stiffness for more than 30 minutes

63.3

0.0165

61.6

<0.0001

Alternating buttock pain

15.9

1.0000

40.3

0.0020

Elevated ESR

40.8

0.1108

42.3

<0.0001

Elevated CRP

45.3

0.0002

48.3

<0.0001

Dactylitis

10.6

0.0451

12.5

<0.0001

Enthesitis

26.1

0.0004

28.1

<0.0001

Tendonitis

22.0

<0.0001

14.2

<0.0001

Active Synovitis

23.3

<0.0001

21.6

<0.0001

Arthritis

42.4

<0.0001

27.8

<0.0001


Disclosure: A. A. Deodhar, AbbVie, Amgen, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB Pharma, 2,Eli Lilly, Janssen, Novartis, Pfizer, UCB Pharma, 2; T. Hunter, Eli Lilly and Company, 3; D. S. Calderon, Eli Lilly and Company, 1,Eli Lilly and Company, 3; S. Lobosco, Adelphi Real World, 3; R. Moon, Adelphi Real World, 3; G. Milligan, Adelphi Real World, 3.

To cite this abstract in AMA style:

Deodhar AA, Hunter T, Calderon DS, Lobosco S, Moon R, Milligan G. Clinical Characteristics and Peripheral Joint Involvement at the Time of Diagnosis of Non-Radiographic Axial Spondyloarthritis Patients in the United States and Europe [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/clinical-characteristics-and-peripheral-joint-involvement-at-the-time-of-diagnosis-of-non-radiographic-axial-spondyloarthritis-patients-in-the-united-states-and-europe/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-characteristics-and-peripheral-joint-involvement-at-the-time-of-diagnosis-of-non-radiographic-axial-spondyloarthritis-patients-in-the-united-states-and-europe/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology